REG - Smith & Nephew Plc - Director/PDMR Shareholding

Smith & NephewAnnouncement

Yesterday 16:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260324:nRSX9555Xa&default-theme=true

RNS Number : 9555X  Smith & Nephew Plc  24 March 2026

SMITH & NEPHEW PLC

 

24 March 2026

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

This announcement is made in accordance with the UK Market Abuse Regulation
(Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the
European Union (Withdrawal) Act 2018).

 

On 23 March 2026, the Company received notification of the following
transactions in US$0.20 ordinary shares (the "Shares") in Smith & Nephew
plc (the "Company") following the vesting of awards under the Smith &
Nephew Global Share Plans 2020 and 2010 and the Smith & Nephew Restricted
Share Plan 2024.

 

1.   VESTING OF 2023 PERFORMANCE SHARE AWARDS MADE UNDER THE GLOBAL SHARE
PLANS 2020 AND 2010.

 

The awards vested on 23 March 2026 and a number of Shares were sold to cover
the tax liability arising on the vesting. The number of Shares acquired
includes the dividend equivalent Shares which participants receive on vested
Shares.  The table below sets out the number of shares under award which
vested.  The remaining shares under award have lapsed.

 

The following relates to individuals included in the below notification:

 

 Reason for the notification
 Initial notification /Amendment                              Initial notification
 Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor
 Name                                                         Smith & Nephew plc
 LEI                                                          213800ZTMDN8S67S1H61
 Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transactions have been conducted
 Description of the financial instrument, type of instrument  Smith & Nephew plc ordinary shares of USD 0.20 each

 Identification code                                          ISIN: GB0009223206
 Nature of the transaction                                    Vesting of awards under the Smith & Nephew Global Share Plans 2020 and
                                                              2010 followed by the sale of shares to cover the relevant tax liabilities.
 Date of Transaction                                          23 March 2026
 Place of Transaction                                         London Stock Exchange (XLON)

 

 

 

 Name                                                                                Price (£)   Volume                                                         Aggregated information

 (Position)                                                                Status
 Deepak Nath                                                               Director  11.938637   109, 650 (of which 44,994 were sold and 64, 656 retained)      N/A Single Transaction

 (Chief Executive Officer)
 Helen Barraclough                                                         PDMR      11.938637   24,047 (of which 11,342 were sold and 12,705 retained)         N/A Single Transaction

 (Group General Counsel and Company Secretary)
 Paul Connolly                                                             PDMR      11.938637   31,789 (of which 9,289 were sold and 22,500 retained)          N/A Single Transaction

 (President Global Operations)
 Craig Gaffin                                                              PDMR      11.938637   14,565 (of which 3,691 were sold and 10,874 retained)          N/A Single Transaction

 (President, Orthopaedics)
 Mizanu Kebede                                                             PDMR      11.938637   32,504 (of which 10,572 were sold and 21,932 retained)         N/A Single Transaction

 (Chief Quality & Regulatory Affairs Officer)
 Elga Lohler                                                               PDMR      11.938637   39,778 (of which 16,023 were sold and 23,755 retained)         N/A Single Transaction

 (Chief HR Officer)
 Vasant Padmanabhan                                                        PDMR      11.938637   38,697 (of which 15,534 were sold and 23,163 retained)         N/A Single Transaction

 (President Research & Development, ENT and Emerging Markets)
 Alison Parkes                                                             PDMR      11.938637   9, 403 (of which 4, 307 were sold and 5 096 retained)          N/A Single Transaction

 (Chief Compliance Officer)

 Scott Schaffner                                                           PDMR      11.938637   56,942 (of which 19,961 were sold and 36,981 retained)         N/A Single Transaction

 (President Sports Medicine)
 Rohit Kashyap                                                             PDMR      11.938637   60,390 (of which 16,309 were sold and 44,081 retained)         N/A Single Transaction

 (President, Advanced Wound Management and Global Commercial Operations)

 

All figures in these columns are stated to 6 decimal places where applicable.

 

2.   VESTING OF DEFERRED BONUS SHARE AWARDS MADE UNDER THE GLOBAL SHARE PLAN
2020

 

The awards vested on 23 March 2026 and a number of Shares were sold to cover
taxation obligations arising on the vesting. The number of Shares acquired
includes the dividend equivalent Shares which participants receive on vested
Shares.

 

The following relates to individuals included in the below notification:

 

 Reason for the notification
 Initial notification /Amendment                              Initial notification
 Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor
 Name                                                         Smith & Nephew plc
 LEI                                                          213800ZTMDN8S67S1H61
 Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transactions have been conducted
 Description of the financial instrument, type of instrument  Smith & Nephew plc ordinary shares of USD 0.20 each

 Identification code                                          ISIN: GB0009223206
 Nature of the transaction                                    Vesting of Deferred Bonus Share awards under the Smith & Nephew Global
                                                              Share Plan 2020 followed by the sale of shares to cover the relevant tax
                                                              liabilities.
 Date of Transaction                                          23 March 2026
 Place of Transaction                                         London Stock Exchange (XLON)

 

 Name                                                                                 Price (£)   Volume                                                  Aggregated information

 (Position)                                                                 Status
 Deepak Nath                                                                Director  11.938637   27,739 (of which 11,383 were sold and 16,356 retained)  N/A Single Transaction

 (Chief Executive Officer)
 Helen Barraclough                                                          PDMR      11.938637   8,793 (of which 4,148 were sold and 4,645 retained)     N/A Single Transaction

 (Group General Counsel and Company Secretary)
 Paul Connolly                                                              PDMR      11.938637   9,099 (of which 3,458 were sold and 5,641 retained)     N/A Single Transaction

 (President Global Operations)
 Craig Gaffin                                                               PDMR      11.938637   5,310 (of which 1,401 were sold and 3,909 retained)     N/A Single Transaction

 (President, Orthopaedics)
 Mizanu Kebede                                                              PDMR      11.938637   9,963 (of which 4,002 were sold and 5,961 retained)     N/A Single Transaction

 (Chief Quality & Regulatory Affairs Officer)
 Elga Lohler                                                                PDMR      11.938637   13,214 (of which 5,325 were sold and 7,889 retained)    N/A Single Transaction

 (Chief HR Officer)
 Vasant Padmanabhan                                                         PDMR      11.938637   12,619 (of which 5,065 were sold and 7,554 retained)    N/A Single Transaction

 (President Research & Development, ENT and Emerging Markets)
 Alison Parkes                                                              PDMR      11.938637   5,550 (of which 2,604 were sold and 2,946 retained.)    N/A Single Transaction

 (Chief Compliance Officer)
 Scott Schaffner                                                            PDMR      11.938637   14,045 (of which 5,147 were sold and 8,898 retained)    N/A Single Transaction

 (President Sports Medicine)
 Rohit Kashyap (President, Advanced Wound Management and Global Commercial  PDMR      11.938637   9,671 (of which 3,445 were sold and 6,226 retained)     N/A Single Transaction
 Operations)

All figures in these columns are stated to 6 decimal places where applicable.

 

 

3.   PARTIAL VESTING OF 2025 RESTRICTED SHARE AWARDS MADE UNDER THE
RESTRICTED SHARE PLAN 2024

 

The awards vested on 23 March 2026 and a number of Shares were sold to cover
taxation obligations arising on the vesting of the awards. The number of
Shares acquired includes the dividend equivalent Shares which participants
receive on vested Shares.

 

The following relates to individuals included in the below notification:

 

 Reason for the notification
 Initial notification /Amendment                              Initial notification
 Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor
 Name                                                         Smith & Nephew plc
 LEI                                                          213800ZTMDN8S67S1H61
 Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transactions have been conducted
 Description of the financial instrument, type of instrument  Smith & Nephew plc ordinary shares of USD 0.20 each

 Identification code                                          ISIN: GB0009223206
 Nature of the transaction                                    Vesting of Restricted Share awards under the Smith & Nephew Restricted
                                                              Share Plan 2024 followed by the sale of shares to cover the relevant tax
                                                              liabilities.
 Date of Transaction                                          23 March 2026
 Place of Transaction                                         London Stock Exchange (XLON)

 

 Name                                                                                 Price (£)   Volume                                                       Aggregated information

 (Position)                                                                 Status
 Deepak Nath                                                                Director  11.938637   45,220 (of which 18,587 were sold and 26,633 retained)       N/A Single Transaction

 (Chief Executive Officer)
 John Rogers                                                                Director  11.938637   13 902 (of which 8, 663 were sold and 5 239 retained)        N/A Single Transaction

 (Chief Financial Officer)
 Helen Barraclough                                                          PDMR      11.938637   7,942 (of which 3,746 were sold and 4,196 retained)          N/A Single Transaction

 (Group General Counsel and Company Secretary)
 Paul Connolly                                                              PDMR      11.938637   7,732 (of which 3,387 were sold and 4,345 retained)          N/A Single Transaction

 (President, Global Operations)
 Craig Gaffin                                                               PDMR      11.938637   13,159 (of which 3,216 were sold and 9,943 retained)         N/A Single Transaction

 (President, Orthopaedics)
 Mizanu Kebede                                                              PDMR      11.938637   8,091 (of which 3,764 were sold and 4,327 retained)          N/A Single Transaction

 (Chief Quality & Regulatory Affairs Officer)
 Elga Lohler                                                                PDMR      11.938637   13,120 (of which 5,309 were sold and 7,811 retained)         N/A Single Transaction

 (Chief HR Officer)
 Vasant Padmanabhan                                                         PDMR      11.938637   10,661 (of which 4,280 were sold and 6,381 retained)         N/A Single Transaction

 (President Research & Development, ENT and Emerging Markets)
 Alison Parkes                                                              PDMR      11.938637   3,441 (of which 1,623 were sold and 1,818 retained)          N/A Single Transaction

 (Chief Compliance Officer)
 Scott Schaffner                                                            PDMR      11.938637   15,437 (of which 6,555 were sold and 8,882 retained)         N/A Single Transaction

 (President Sports Medicine)
 Rohit Kashyap (President, Advanced Wound Management and Global Commercial  PDMR      11.938637   16,161 (of which 6,383 were sold and 9,778 retained)         N/A Single Transaction
 Operations)

All figures in these columns are stated to 6 decimal places where applicable.

 

 

Philip Horner

Group Deputy Company Secretary

Smith & Nephew plc

 

Tel:  +44 (0)1923 477100

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFLRVEISFIR



            Copyright 2019 Regulatory News Service, all rights reserved